RxDoctor Payments Data

Nicolaus Winters, MD

Pain Medicine · Evansville, INNPI 1750522660

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $7,265 of the $8,574 with a category attached, or 84.7%. Abbott accounts for 69.5% of it on its own, with 30 other manufacturers making up the rest. Reporting peaked in 2024 at $1,925 and has fallen 66.6% since, to $644 in 2025.

$8,574in general payments, 2019–2025

Across 349 payments — averaging $24.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$6K
  • Amgen$624
  • AbbVie$524
  • Novartis$196
  • Vertos Medical, Inc.$162
  • Si-bone, Inc.$96
  • plus $1K from 25 others

What the payments were for

  • Consulting fees$1,23314%
  • Food & beverage$7,26585%
  • Education$771%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,574 in reported general payments places this provider in the 75th percentile of 128 pain medicine providers in Indiana.

See all pain medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$987,478
Medicare patients
928
Services billed
15,143

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen1,361$40,594
BelbucaBuprenorphine Hcl43$24,264
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen900$19,542
Buprenorphine61$18,966
OxycontinOxycodone Hcl13$7,964
Fentanyl40$6,141
Gabapentin345$4,374
Pentazocine-Naloxone HclPentazocine Hcl/Naloxone Hcl33$4,271
AmantadineAmantadine Hcl27$3,600
Oxycodone Hcl144$3,486
Pregabalin155$3,318
Morphine Sulfate ErMorphine Sulfate66$2,116
Hydromorphone Hcl54$803
Meloxicam25$684
Morphine Sulfate24$551

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca$35$24,26443 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 128 pain medicine providers in Indiana.

Other pain medicine in Evansville

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →